Since blocking senescence with Ang‐(1‐7) might promote dysplasia or neoplasia of endothelial cells, or Ang‐(1‐7) may itself exert hypotension or cardiac and renal fibrosis (Shao et al., 2008; Velkoska, Dean, Griggs, Burchill, & Burrell, 2011), further clinical studies will be needed to assess not only the efficacy but also the safety and tolerability of the therapeutic use of Ang‐(1‐7). This evidence concerns the gene ANG and neoplasm.